Skip to main content
Close

Centre for the North

If you are interested in more information about a particular trial, please talk with your treating physician first, and they may contact this centre for further information if necessary.

Tumour Group / Site

Trial Title/Summary

Opening Date

CENTRAL NERVOUS SYSTEM (CNS) 

Feasibility study of randomization to 20 Gy in 5 fractions whole brain radiotherapy versus 15 Gy in one fraction volumetric modulated arc therapy for one to ten brain metastases (BRAT).

The purpose of this study is to determine whether it is feasible to open a phase III clinical trial comparing the effectiveness of whole brain radiotherapy to single radiation treatment of brain metastases only.

Status: On follow-up of accrued patients

Mar 2014

Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors: A randomized phase II trial (SABR-COMET).

The purpose of this study is to assess the impact of stereotactic ablative radiotherapy on overall survival and quality of life in patients with metastatic cancer lesions in comparison to the standard of care treatment.

Status: On follow-up of accrued patients

Jun 2016

Phase II non-randomized trial of stereotactic ablative radiotherapy for oligometastases (SABR - 5).

The purpose of this study is to assess the quality of life and side effects in patients with metastatic cancer lesions who are being treated with a comprehensive oligometastatic SABR treatment program.

Status: Actively accruing patients

Jan 2017
HEAD AND NECK

A phase II randomized trial for early-stage squamous cell carcinoma of the oropharynx: Radiotherapy vs. trans-oral robotic surgery (ORATOR).

The purpose of this study is to compare the quality of life after primary radiotherapy to trans-oral robotic surgery in patients with early stage oropharynx cancer. 

Status: On follow-up of accrued patients

Jan 2017
BREAST

A prospective cohort study evaluating risk of local recurrence following breast conserving surgery and endocrine therapy in low risk Luminal A breast cancer (LUMINA).

The purpose of this study is to determine whether Luminal A subtype breast cancer combined with other factors, such as tumour size and extent of disease, can identify a patient as having very low risk for reoccurrence following breast conserving surgery, and therefore not needing radiation therapy after breast conserving surgery. 

Status: On follow-up of accrued patients

Apr 2014

A multi-centre randomized trial to determine if accelerated partial breast irradiation, utilizing 3D CRT, is as effective as whole breast irradiation following breast conserving surgery in women with ductal carcinoma in situ or invasive breast cancer with negative axillary lymph nodes (RAPID).

The purpose of this study is to assess the effectiveness of whole breast radiation in comparison to partial breast radiation. Effectiveness will be determined by rate of tumour recurrence.  

Status: On follow-up of accrued patients

Sep 2012
GU-
PROSTATE

Improving Quality of Life (QOL) after optimal radiotherapy for intermediate and high risk prostate cancer: HDR vs. LDR brachytherapy boost (QOL - HDR vs LDR).

The purpose of this study is to compare the quality of life in prostate cancer patients treated with low dose rate (LDR) brachytherapy in comparison to high dose rate (HDR) brachytherapy.

Status: Actively accruing patients

Sep 2014

Androgen suppression combined with elective nodal and dose escalated radiation therapy (ASCENDE).

The purpose of this study is to compare androgen suppression and elective pelvic nodal irradiation followed by a high dose radiation therapy to androgen suppression and elective pelvic nodal irradiation followed by an Iodine brachytherapy implant for patients with intermediate to high risk prostate cancer.

Status: On follow-up of accrued patients

Aug 2013

Androgen suppression with stereotactic body or external beam radiation therapy: A phase II randomized trial for intermediate and high risk prostate cancer (ASSERT).

The purpose of this study is to compare the rates of acute and late toxicities of stereotactic ablative radiotherapy with conventional external beam radiation, as well as determine what proportion of potential participants will agree to participate and be randomized.

Status: Actively accruing patients

Mar 2017
SOURCE: Centre for the North ( )
Page printed: . Unofficial document if printed. Please refer to SOURCE for latest information.

Copyright © BC Cancer Agency. All Rights Reserved.

    Copyright © 2017 Provincial Health Services Authority